Relationship between tumor necrosis factor alpha and interleukin-10 and left ventricular remodeling in renal failure


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. evaluation of the relationship between the cytokine profile and the type of left ventricular hypertrophy in renal failure. material and methods. 55 patients with renal failure (RF) and left ventricular hypertrophy (LVH) aged 24 to 79 years, mean age 52.7±13.з years, 36 men (65.4%), 19 women (34.6%), were examined. all patients underwent clinical, echocardiographic and laboratory examination. the blood tumor necrosis factor alpha (TNF-а), interleukin (IL)-io, cystatin c, creatinine, electrolytes, c-reactive protein and uric acid levels, as well as the blood lipids were determined. the glomerular filtration rate (GFR) was calculated based on cystatin c and blood creatinine. depending on the lvh types, patients were divided into two subgroups: concentric (n=20) and eccentric lvh (n=35) with rf. results. in the subgroup of patients with eccentric lvh and rf, the mean values of body mass index (30.4±5.2 versus 28.i±5.7 kg/m2; р=0.013), left ventricle end-diastolic diameter (5.37±o.80 versus 4.96±o.52 cm; р=0.044), and the end diastolic volume (134.4±27.i versus 116.з±26.4 ml; р=0.038) were significantly higher than subgroup with concentric lvh and rf. a significant increase in the interventricular septum (ivs) thickness (1.23±o.20 versus o.94±o.14 cm; р=0.005), the left ventricular posterior wall (LVPW) thickness (1.22±o.19 versus o.93±o.13 cm; р=0.005) and relative wall thickness (RWT) (0.50±0.07 versus 0.35±0.04 U; Р =0.005) WERE OBSERVED IN PATIENTS WITH CONCENTRIC LVH AND RF. A STATISTICALLY SIGNIFICANT DIRECT correlation between the tnf-alpha level and the lv myocardium mass index was recorded (r=0.356; р=0.010), lvpw thickness (R=0.401; P=0.011) AND RWT (R = 0.325; P=0.045). Conclusion. in patients with renal failure and eccentric lvh, an increase in body mass index, left ventricle end-diastolic diameter AND END DIASTOLIC VOLUME WAS RECORDED. MEANWHILE, IN INDIVIDUALS WITH CONCENTRIC LVH AND RF, THERE WAS AN INCREASE IN THE interventricular septum thickness, lv posterior wall thickness, and the relative wall thickness. an increase in lv myocardial mass index was associated with an increase in tnf-alpha level, and an increase in lv wall thickness - WITH INCREASE in il-10 level.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; Kyrgyz-Russian Slavic University

Email: murkamilov.i@mail.ru
Cand. Sci. (Med.), Deputy Associate Professor at the Department of Faculty Therapy, I.K. Akhunbaev KSMA; Senior Lecturer of the Department of Therapy №2 in the specialty “General Medicine”

I. Sabirov

Kyrgyz-Russian Slavic University

Email: sabirov_is@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Therapy №2 in the specialty “General Medicine”

V. Fomin

Sechenov University Moscow

Email: fomin_vic@mail.ru
Dr. Sci. (Med.)., Professor, Corresponding Member of RAS, Head of the Department of Faculty Therapy №1, N.F. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Clinical Work and Postgraduate Professional Education

Zh. Murkamilova

Kyrgyz-Russian Slavic University

Email: murkamilovazh.t@mail.ru;orcid:org/0000-0002-7653-0433
Correspondence Post-Graduate Student at the Department of Therapy № 2 in the specialty “General Medicine”

I. Kudaibergenova

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: k_i_o2403@mail.ru
Dr. Sci. (Med.), Professor, Rector

F. Yusupov

Osh State University

Email: furcat_y@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry, Faculty of Medicine, Chief Neurologist of the Southern Region of Kyrgyzstan

Әдебиет тізімі

  1. Мухин Н.А. Нефрология. Национальное руководство. Краткое издание. М., 2018. 608 с. [Mukhin N.A. Nephrology. National leadership. M., 2018. 608р. (In Russ.)].
  2. Шилов Е.М. Нефрология. М., 2008. 688 с. [Shilov EM. Nephrology. М., 2008. 688 p. (In Russ.)].
  3. Wang J., Wang W., Guo W., et al. Clinical importance of chemokines and inflammatory cytokines for patient carefollowing percutaneous nephrolithotripsy. Exp. Ther. Med. 2018;15:2:2189-95. https://doi.org/10.3892/etm.2017.5645
  4. Chow F., Ozols E., Nikolic-Paterson D.J., et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116-12
  5. Бондарь И.А., Климонтов В.В., Парфентьева Е.М. Фиброгенные и анти-фиброгенные факторы роста в развитии диабетической нефропатии. Сиб. мед. журн. (Томск). 2011;26(4-2):10-5. [BondarI.A., Klimontov V.V., Parfentyeva E.M. Profibrotic and antifibrotic growth factors in the development of diabetic nephropathy. Sib. Med. J. (Tomsk). 2011;26(4-2):10-5. (In Russ.)].
  6. Козловская Л.В., Бобкова И.Н., Нанчикеева М.Л. и др. Общие молекулярно-клеточные механизмы ремоделирования почек и сердца при хронической болезни почек - мишень нефрокардиопротекции. Тер. архив (архив до 2018 г.).2013;85(6):66-72. [Kozlovskaya L.V., Bobkova I.N., Nanchikeeva M.L., et al. General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection. Ter. Arkh. 2013;85(6):66-72. (In Russ.)].
  7. Кутырина И.М., Руденко Т.Е., Швецов М.Ю., Кушнир В.В. Факторы риска сердечно-сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности. Тер. архив. 2006;78(5):45-50 [Kutyrina I., Rudenko T., Shvetsov M.Iu., Kushnir V.V. Risk factors of vascular complications in patients at a predialysis stage of chronic renal failure. Ter. Arkh. 2006;78(5):45-50. (In Russ.)].
  8. Bahramali E., Firouzabadi N., Rajabi, et al. Association of renin-angiotensin- aldosterone system gene polymorphisms with left ventricular hypertrophy in patients with heart failure with preserved ejection fraction: A case-control study. Clin. Exp. Hypertensi. 2017;39:4:371-76. https://doi.org/10.1080/1064196 3.2016.1267196
  9. Levey A.S., Coresh J., Bolton K., et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39(2 Suppl. 1):1-266.
  10. Levey A.S., Inker L.A., Coresh J. GFR estimation: from physiology to public health. Am. J. Kidney Dis. 2014;63:5:820-34. Doi: https://doi.org/10.1053/j. ajkd.2013.12.006.
  11. Hoek F.J., Kemperman F.A.W., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplantat. 2003;18(10):2024-31. https://doi.org/ 10.1093/ndt/gfg349
  12. Парфенов А.С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратно-программного комплекса «Ангиоскан-01». Поликлиника. 2012;2(1):70-4.
  13. Teichholz L.E., Kreulen T., Herman M.V. Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlation. Am. J. Cardiol. 1976;37(1):7-11. https://doi.org/10.1016/0002-9149(76)90491-4
  14. Devereux R.B., Reichek N. Echocardiographic determination of the left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;5(4):613-18. PMID: 138494.
  15. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39(33):3021-104. https://doi.org/10.1097/ HJH.0000000000001940
  16. Гринхальх Т. Основы доказательной медицины. М., 2004. 240 с. [Grinhalh T. Fundamentals of Evidence-Based Medicine. M., 2004. 240р. (In Russ.)].
  17. Major R.W., Cheng M.R., Grant R.A., et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PloS One. 2018;13(3):e0192895.
  18. Di Lullo L., Gorini A., Russo D., et al. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal. Med. 2015;5(4):254-66. https://doi.org/10.1159/000435838
  19. Муркамилов И.Т., Айтбаев К.А., Сарыбаев А.Ш. и др. Взаимосвязьремо-делирования сонных артерий и геометрии левого желудочка у вольных с хроническим гломерулонефритом. Кардиология. 2018;58(4):45-2. https:// doi.org/10.18087/cardio.2018.4.10108. [Murkamilov I.T., Aitbaev K.A., Sarybaev A.S., et al. Relationship of Remodeling of Carotid Arteries and Left Ventricular Geometry in Patients With Chronic Glomerulonephritis. Kardiol. 2018;58(4):45-2. (In Russ.)]
  20. Минушкина Л.О., Чумакова О. С., Селезнева Н. Д. и др. Развитие гипертрофии левого желудочка, ассоциированное с генетическим полиморфизмом медиаторов системы воспаления. Рос. кардиол. журн. 2014;(10):23- 8. https://doi.org/10.15829/1560-4071-2014-10-23-8
  21. Moubarak M., Jabbour H., Smayra V., et al. Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol. Res. 2012;61(1):13-24.
  22. Wang X., Lin Y. Tumor necrosis factor and cancer, buddies or foes? 1. Acta Pharmacol. Sinica. 2008;29(11):1275-88. https://doi.org/10.1111/j. 1745-7254.2008.00889.x
  23. Vielhauer V., Mayadas T.N. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Seminars in nephrology. W.B. Saunders. 2007;27:3:286-308. https://doi. org/10.1016/j.semnephrol.2007.02.004
  24. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990;323(4):236-41. https://doi.org/10.1056/NEJM199007263230405
  25. Добродеева Л.К., Жилина Л.П. Иммунологическая реактивность, состояние здоровья населения Архангельской области. Екатеринбург, 2004. 228 с. [Dobrodeeva L.K., Zhilina L.P. Immunoreactivity and Health Status of the Arkhangelsk Region Population. Yekaterinburg, 2004. 228p. (In Russ.)].
  26. Amdur R.L., Feldman H.I., Gupta J., et al. Inflammation and progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol. 2016;11(9):1546-56. https://doi.org/10.2215/CJN.13121215
  27. Tonelli M., Sacks F., Pfeffer M., et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68(1):237-45. https:// doi.org/ie.lHlfj.1523-1755.2755.20050.0.
  28. Takei Y., Di Tullio M.R., Homma S., et al. Soluble tumor necrosis factor receptor 1 level is associated with left ventricular hypertrophy: the northern Manhattan study. Am. J. Hyperten. 2009;22:763-69. https://doi.org/10.1038/ ajh.2009.79
  29. Gohda T., Maruyama S., Kamei N., et al. Circulating TNF receptors 1 and 2 predict mortality in patients with end-stage renal disease undergoing dialysis. Sci. Reports. 2017;7:43520.
  30. Bae E., Cha R.H., Kim Y.C., et al. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Med. 2017;96:19. https://doi.org/10.1097/MD.0000000000006666
  31. Alwahaibi N.Y., Alissaei H.K., Alshihi S.A., et al. Serum levels of TNF-a, IL-6 and IL-10 in haemodialysis and renal transplant patients and in healthy sub3ects. Portuguese J. Nephrol. Hypertens. 2016;30(3):194-98.
  32. Didion S.P., Kinzenbaw D.A., Schrader L.I., et al. Endogenous interleukin-10 inhibits angiotensin II-induced vascular. Hypertens. 2009;54(3):619-24.
  33. Tinsley J.H., South S., Chiasson V.L., et al. Interleukin-10 reduces infl ammation, endothelial dysfunction, and blood pressure in hypertensive pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010;298(3):713-19.
  34. Муркамилов И.Т., Фомин В.В., Айтбаев К.А. и др. Цитокиновая модель развития сердечно-сосудистых осложнений при хронической болезни почек. Клин. нефрология. 2017;2:71-5. [Murkamilov I.T., Fomin V.V., Aitbaev K.A., et al. Cytokine model of the development of cardiovascular complications in chronic kidney disease. Clin. Nephrol. 2017;2:71-5. (In Russ.)].
  35. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Цитокины и артериальная жесткость на ранней стадии хронической болезни почек: взаимосвязь и прогностическая роль. Клин. нефрология. 2018;4:25-32

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>